Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab-Reference-Cited by-同舟云学术

Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab

Published:2019-03-15 Issue:10 Volume:21 Page:1413-1423
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Manneh Kopp R. A.,Sepúlveda-Sánchez J. M.,Ruano Y.,Toldos O.,Pérez Núñez A.,Cantero D.,Hilario A.,Ramos A.,de Velasco G.,Sánchez-Gómez P.,Hernández-Laín A.^ORCID

Funder

GEINO

Instituto de Salud Carlos III

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-019-02070-6.pdf

Reference35 articles.

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.

2. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8:610–22.

3. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008;26:271–8.

4. Poulsen HS, Urup T, Michaelsen SR, Staberg M, Villingshøj M, Lassen U. The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. Cancer Manag Res. 2014;6:373–87.

5. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy;Discover Oncology;2024-03-22

2. Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in glioblastoma;Neuro-Oncology;2024-02-27

3. Clinical Benefit of Bevacizumab and Irinotecan (BEV+IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors;Anticancer Research;2022-12

4. Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review);International Journal of Oncology;2022-04-19

5. The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab;Scientific Reports;2021-03-16